A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-99
SponsorNational Cancer Centre, Singapore
About this trial
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.
This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed advanced NSCLC
Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)
Male or female adults, age as defined by local regulations
Disqualifiers
None
Trial population
Patients with advanced EGFR exon 20 insertion mutated NSCLC.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall survival (OS)
Time from diagnosis to death.
Time frame
Up to 10 years.2
Duration of therapy (DOT)
Time from start of treatment regimen to end of treatment regimen.
Time frame
Up to 10 years.3
Real-world progression-free survival (PFS)
Time from start of treatment regimen to disease progression or death.
Time frame
Up to 10 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov